A patent review of PRMT5 inhibitors to treat cancer (2018-present)
文献类型：期刊论文
| 作者 | Gao, Jing1; Yang, Jie1; Xue, Shengyu2,3; Ding, Hong3 ; Lin, Hua1; Luo, Cheng2,3,4,5,6
|
| 刊名 | EXPERT OPINION ON THERAPEUTIC PATENTS
 |
| 出版日期 | 2023-04-28 |
| 页码 | 28 |
| ISSN号 | 1354-3776 |
| 关键词 | PRMT5 inhibitor epigenetic target cancer treatment combined treatment |
| DOI | 10.1080/13543776.2023.2201436 |
| 通讯作者 | Luo, Cheng(cluo@simm.ac.cn) |
| 英文摘要 | IntroductionProtein arginine methyltransferase 5 (PRMT5) belongs to type II arginine methyltransferases. Since PRMT5 plays an essential role in mammalian cells, it can regulate various physiological functions, including cell growth and differentiation, DNA damage repair, and cell signal transduction. It is an epigenetic target with significant clinical potential and may become a powerful drug target for treating cancers and other diseases.Areas coveredThis review provides an overview of small-molecule inhibitors and their associated combined treatment strategies targeting PRMT5 in cancer treatment patents published since 2018, and also summarizes the progress made by several biopharmaceutical companies in the development, application, and clinical trials of small-molecule PRMT5 inhibitors. The data in this review come from WIPO, UniProt, PubChem, RCSB PDB, National Cancer Institute, and so on.Expert opinionMany PRMT5 inhibitors have been developed with good inhibitory activities, but most of them lack selectivities and are associated with adverse clinical responses. In addition, the progress was almost all based on the previously established skeleton, and more research and development of a new skeleton still needs to be done. The development of PRMT5 inhibitors with high activities and selectivities is still an essential aspect of research in recent years. |
| WOS关键词 | METHYLTRANSFERASE 5 PRMT5 ; PROTEIN ARGININE METHYLTRANSFERASES ; SYMMETRIC DIMETHYLATION ; METHYLATION ; DISCOVERY ; OPPORTUNITIES ; DEGRADATION ; METHYLOSOME ; TARGET ; GROWTH |
| 资助项目 | National Centre for Protein Science Shanghai (Protein Expression and Purification system) ; National Key R&D Program of China[2022YFC3400500] ; National Key R&D Program of China[2021ZD0203900] ; Fujian Provincial Natural Science Foundation[2021J01203] ; National Natural Science Foundation of China[91853205] ; National Natural Science Foundation of China[81821005] ; National Natural Science Foundation of China[92253303] ; National Multidisciplinary Innovation Team of Traditional Chinese Medicine - National Administration of Traditional Chinese Medicine[ZYYCXTD-202004] ; High-level new RD institute[2019B090904008] ; High-level Innovative Research Institute[2021B0909050003] ; Department of Science and Technology of Guangdong Province |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | TAYLOR & FRANCIS LTD |
| WOS记录号 | WOS:000977781500001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/306478]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Luo, Cheng |
| 作者单位 | 1.Fujian Normal Univ, Coll Life Sci, Biomed Res Ctr South China, Fuzhou, Peoples R China 2.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China 4.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan, Peoples R China 5.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou, Peoples R China 6.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China |
| 推荐引用方式 GB/T 7714 | Gao, Jing,Yang, Jie,Xue, Shengyu,et al. A patent review of PRMT5 inhibitors to treat cancer (2018-present)[J]. EXPERT OPINION ON THERAPEUTIC PATENTS,2023:28. |
| APA | Gao, Jing,Yang, Jie,Xue, Shengyu,Ding, Hong,Lin, Hua,&Luo, Cheng.(2023).A patent review of PRMT5 inhibitors to treat cancer (2018-present).EXPERT OPINION ON THERAPEUTIC PATENTS,28. |
| MLA | Gao, Jing,et al."A patent review of PRMT5 inhibitors to treat cancer (2018-present)".EXPERT OPINION ON THERAPEUTIC PATENTS (2023):28. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。